12月19日，港股三大指数高开高走，截至收盘，恒生指数上涨0.75%，恒生科技指数上涨1.12%，恒生国企指数上涨0.68%。 【导读】港股三大指数集体收涨 创新药、新能源汽车等涨幅靠前 具体来看，当日权重科技股集体上涨，腾讯、快手、网易、美团、百度均涨超1%。 板块方面，当日创新药概念股涨幅靠前，其中，映恩生物涨幅达9.29%，药明生物涨幅达4.4%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | | 9606 | 映恩生物-B | 336.600c | 28.600 | 9.29% | | 2269 | 药明生物 | 34.160c | 1.440 | 4.40% | | 6990 | 科伦博泰生物-B | 419.200c | 14.200 | 3.51% | | 1877 | 君实生物 | 23.240c | 0.760 | 3.38% | | 2162 | 康诺亚-B | 55.500c | 1.800 | 3.35% | | 2268 | 药明合联 | 70.000c | 2.050 | 3.02% | | 1530 | ...

【导读】港股三大指数集体收涨 中国基金报记者 忆山 12 月 19 日，港股三大指数高开高走，截至收盘，恒生指数上涨 0.75% ，恒生科技指数上涨 1.12% ，恒生国企指数上涨 0.68% 。 创新药、新能源汽车等涨幅靠前 具体来看，当日权重科技股集体上涨，腾讯、快手、网易、美团、百度均涨超 1% 。 板块方面，当日创新药概念股涨幅靠前，其中，映恩生物涨幅达 9.29% ，药明生物涨幅达 4.4% 。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 - | | --- | --- | --- | --- | --- | | 9606 | 映恩生物-B | 336.600c | 28.600 | 9.29% | | 2269 | 药明生物 | 34.160c | 1.440 | 4.40% | | 6990 | 科伦博泰生物-B | 419.200c | 14.200 | 3.51% | | 1877 | 君实生物 | 23.240c | 0.760 | 3.38% | | 2162 | 康诺亚-B | 55.500c | 1.800 | 3.35% | | 2268 | 药明合联 | 70.000c ...

Market Overview - US inflation slowdown supports interest rate cut expectations, while the Bank of Japan raised rates by 25 basis points, leading to a rise in Hong Kong's three major indices. The Hang Seng Index increased by 0.75% to 25,690.53 points with a total turnover of HKD 221.186 billion [1] - The Hang Seng Index experienced a cumulative decline of 1.1% for the week, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.96% and 2.82%, respectively [1] Blue Chip Performance - Shenzhou International (02313) led the decline among blue chips, falling by 3.18% to HKD 60.95, with a turnover of HKD 490 million, negatively impacting the Hang Seng Index by 2.67 points. Despite exceeding market expectations in revenue and profit, the company's net profit dropped by 32% year-on-year due to declining profit margins and pressures on direct sales [2] - Other notable blue chip performances included WuXi Biologics (02269) rising by 4.4% and Li Auto-W (02015) increasing by 3.81% [2] Sector Highlights - Large tech stocks mostly rose, with Tencent, Kuaishou, and Meituan each gaining over 1%. The L3-level autonomous driving sector saw significant activity, while pharmaceutical stocks rebounded sharply [3] - The L3-level autonomous driving concept stocks surged, with Youjia Innovation (02431) up by 31.22% and Xiaopeng Motors-W (09868) rising by 7.65%. The Ministry of Industry and Information Technology's approval of L3-level autonomous driving vehicles is expected to accelerate the industry's value reconstruction [3] - Pharmaceutical stocks also saw a notable rebound, with Kelaiying (06821) increasing by 10.42% and WuXi Biologics (02269) up by 4.4%. The geopolitical concerns regarding China's CXO industry are expected to stabilize, supporting innovation in the sector [4] Lithium Industry - Lithium stocks experienced a rally, with Ganfeng Lithium (01772) rising by 1.87% and Tianqi Lithium (09696) increasing by 1.72%. The price of lithium carbonate futures broke through the 110,000 yuan mark [4][5] Robotics Sector - The robotics sector was active, with Hong Kong Robot (00370) rising by 10.29%. Recent collaborations in the humanoid robot space are expected to drive market growth, with projections indicating a potential market size of USD 5 trillion by 2050 [6] Notable New Listings - New listings showed a stark contrast, with Zhihui Mining (02546) surging by 90.69% while Xidi Intelligent Driving (03881) fell by 13.69% on their debut [7] Company-Specific Developments - CIMC Group (02039) saw a strong performance, rising by 15.47% after announcing a buyback plan for H-shares worth up to HKD 300 million [8] - Changfei Optical Fiber (06869) climbed by 12.01%, driven by signs of recovery in the traditional optical fiber market and growth in the overseas special optical fiber market [9] - China Duty Free Group (01880) rose by 6.88% following the launch of the Hainan Free Trade Port, with expectations of increased offshore duty-free sales [10] - China Tobacco Hong Kong (06055) increased by 6.68% amid new regulations aimed at strengthening electronic cigarette oversight, with positive outlooks for the tobacco sector [11]

Group 1 - The Hong Kong stock market indices rose significantly on December 19, with the biopharmaceutical sector leading the gains [1] - The Hong Kong Innovative Drug ETF (159567) increased by 2.31%, with a trading volume exceeding 656 million yuan and a turnover rate of over 7.9%, indicating active trading [1] - Notable individual stocks included InnoCare Pharma-B rising over 8%, Lepu Biopharma-B increasing over 5%, and 3SBio rising over 4% [1] Group 2 - Two Phase III clinical study results led by a Chinese research team on Marsduo peptide were published in the British journal Nature, focusing on its use in type 2 diabetes patients [1] - The studies, DREAMS-1 and DREAMS-2, were based on clinical data from Chinese patients and involved collaboration with leading experts and institutions in the field [1] - According to Dongfang Caifu Securities, China's innovative drug companies are entering a period of intensive pipeline harvest, with the market expected to exceed 400 billion yuan in 2024 [1] Group 3 - The number of approved domestic innovative drugs during the "14th Five-Year Plan" period is projected to be 113, which is 2.8 times that of the "13th Five-Year Plan" period [1] - The total amount of innovative drug License-out projects has reached a new record, with preclinical projects accounting for 68%, indicating growing global recognition of Chinese innovations [1] Group 4 - The Hong Kong Innovative Drug ETF closely tracks the National Index for Hong Kong Stock Connect Innovative Drugs, featuring leading stocks such as BeiGene, Innovent Biologics, and 3SBio [2] - The ETF includes several AI-driven pharmaceutical leaders, suggesting a high proportion of innovative drug companies, which may exhibit high elasticity as the AI-enabled innovative drug market expands [2]

12月19日，港股全线反弹，午后继续冲高，港股创新药、港股互联网、港股芯片硬科技齐刷刷领涨。热 门ETF方面，重仓互联网龙头的港股互联网ETF（513770）午后冲高涨逾2%；高弹性港股通创新药ETF （520880）早盘一度涨逾2.5%，现涨近2%；全市场首只聚焦"港股芯片"产业链的港股信息技术ETF （159131）午后维持强势，现涨1.5%。 资金正在积极行动：截至12月18日，港股通创新药ETF（520880）连续9日获净申购，最新基金份额升 至41.78亿份，创上市新高。港股互联网ETF（513770）近10日连续吸金合计高达13.3亿元。 中信建投最新研报指出，港股在经历了9月的单边上涨后，10月以来随着海外宏观预期反复的影响经历 了震荡调整。当前AH两地正同步完成中期调整，港股部分优质资产重新进入高性价比区间，在盈利预 期修复及年末海内外宏观环境改善的共振下，港股正迎来一个不容忽视的岁末交易窗口。 创新药自9月起进入阶段调整期，港股通创新药ETF（520880）标的指数一度回撤逾22%。把握港股创 新药低吸窗口期，重点关注同类最大港股通创新药ETF（520880）及其场外联接基金（025221） ...

Group 1 - The core viewpoint of the article highlights the continuous growth in the scale of license-out transactions for Chinese innovative drugs, with a cumulative transaction value expected to reach $124.4 billion by November 2025, representing a 150% increase compared to 2024 [1] - The announcement from Heptares Therapeutics indicates a global strategic cooperation and licensing agreement with BMS, which could yield up to $1.035 billion in development and commercial milestone payments, along with tiered royalties, further validating the high-quality development status of the Chinese innovative drug industry [1] - The uncertainty surrounding overseas policies is decreasing, as the U.S. Senate has passed a revised version of the Biosecurity Act as part of the National Defense Authorization Act for fiscal year 2026, which is expected to be approved by the House and signed by the President, creating a more predictable environment for innovative drug companies with global collaboration potential [1]

Group 1 - The core viewpoint of the article highlights a significant rise in Hong Kong's innovative pharmaceutical stocks, with companies like InnoCare Pharma-B and Lepu Biopharma-B seeing increases of over 7% and 5% respectively, driven by the addition of 111 new drugs to the national medical insurance catalog, marking a record high in both quantity and proportion [1] - The new catalog includes 50 first-class new drugs, indicating a strong trend towards innovation in the pharmaceutical sector, which is expected to continue into 2026, focusing on "innovation + internationalization" as the core theme [1] - The Hang Seng Innovative Drug ETF (159316) has attracted significant capital, with a net inflow of 236 million yuan over the past 10 days, bringing its total size to 4.086 billion yuan, reflecting strong investor interest in the innovative drug sector [1] Group 2 - The article notes that the innovative drug industry is expected to maintain an upward trend, with a focus on companies that demonstrate global competitiveness and successful commercialization [1] - The medical device industry is also experiencing a phase of easing factors, with innovation and internationalization accelerating, suggesting potential improvements by 2026 [1] - The Hang Seng Innovative Drug ETF is the only product tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which excludes CXO companies and focuses on core enterprises in the innovative drug industry, providing investors with a convenient tool for exposure to leading companies [1]

Group 1 - The core viewpoint of the news highlights a positive outlook for the pharmaceutical and biotechnology industry in China, with multiple favorable trends expected by 2025 [1] - The medical device procurement market is recovering, with a year-on-year growth of 29.8% in Q3 2025, indicating a turning point in revenue for medical device companies [1] - The domestic centralized procurement and normalization of anti-corruption in healthcare are driving companies to seek high-margin markets abroad [1] Group 2 - The innovative drug sector is entering a period of significant pipeline development, with the market size expected to exceed 400 billion yuan in 2024 and 113 domestic innovative drugs approved during the "14th Five-Year Plan" period [1] - Record amounts of license-out agreements for Chinese innovative drugs have been achieved, with 68% of preclinical projects focusing on emerging therapies such as ADCs and bispecific antibodies [1] - The government is actively supporting brain-computer interface policies, with technological advancements from companies like Neuralink accelerating industrialization [1] Group 3 - The industry valuation is approaching the 10-year average level, with public fund holdings gradually increasing [1] - The commercial health insurance payment system is improving, which is expected to facilitate the transition of innovative drug payments from a single medical insurance model to a multi-payment model [1] - The chemical pharmaceutical sector is leading the market, driven by innovative drugs and AI healthcare, with noticeable differentiation in sub-sectors [1]

港股上午盘三大指数集体上涨，恒生指数涨0.65%，国企指数涨0.5%，恒生科技指数涨1.14%，市场情 绪回暖。权重科技股拉升助力大市上行，其中美团涨超2%，腾讯、百度涨超1%；医药类股全线上涨， 机构预计2026年创新药景气度将持续向上，创新药概念股涨幅靠前；中资券商股、芯片股、铜业股普 涨。另外，石油股、影视股、体育用品股普跌，昨日强势领涨的航空股多数弱势。(格隆汇) ...

Market Overview - The A-share market showed positive performance with the Shanghai Composite Index up by 0.59%, the Shenzhen Component Index up by 0.93%, and the ChiNext Index up by 0.99% at midday [2][3]. Sector Performance - Retail stocks surged, leading the market with significant gains in sectors such as duty-free shops and dairy products. Notable stocks included Debi Group, Dalian Friendship, and Xiwang Food, which hit the daily limit [4][5]. - The consumer sector continued to rise, with strong performances in retail, food and beverage, and reward economy sectors. The Ministry of Commerce and the Ministry of Finance recently issued a notice to pilot new consumption formats in 50 cities, which may further boost this sector [5]. - Other active sectors included nuclear power, cross-strait integration, rare earth permanent magnets, stablecoins, robotics, and innovative pharmaceuticals [2][4]. Trading Volume and Market Activity - The total trading volume in the Shanghai and Shenzhen markets reached 1.09 trillion yuan, an increase of 42.1 billion yuan compared to the previous trading day, with nearly 4,700 stocks rising [4]. - The ChiNext Index opened strong, with a notable increase in trading activity in sectors like CPO, controlled nuclear fusion, and consumer electronics [8][10]. Notable Stock Movements - The newly listed stock Yuxun Co. saw a remarkable increase of over 360% on its first trading day [11]. - The Hang Seng Index opened up by 0.53%, with tech stocks like NetEase, Alibaba Health, and Kuaishou showing strong performance [12]. Economic Indicators - The People's Bank of China conducted a 562 billion yuan reverse repurchase operation with a 1.40% interest rate, indicating ongoing liquidity support in the market [13].